{"id":"W2980301843","doi":"10.1182/blood.v120.21.1862.1862","title":"Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Veliparib; Bortezomib; PARP inhibitor; Medicine; Proteasome inhibitor; Multiple myeloma; Internal medicine; Ixazomib; Pharmacology; Carfilzomib; Plasma cell leukemia; Oncology; Tolerability; Cancer research; Adverse effect; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001230491,0.001443182,0.003117995,0.0005191618,0.0005097213,0.001297698,0.001060419,0.001019871,0.00275015],"category_scores_gemma":[0.0008071674,0.0007961979,0.001330641,0.0005517672,0.0007758415,0.0007355676,0.0004635128,0.00343763,0.0007951667],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001120798,"about_ca_system_score_gemma":0.001447265,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008852885,"about_ca_topic_score_gemma":0.002026086,"domain_scores_codex":[0.9995502,0.0001762275,0.00002372193,0.00009348266,0.00005174975,0.0001046894],"domain_scores_gemma":[0.9994898,0.00006450765,0.00009571192,0.00004586141,0.00003127533,0.0002729607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6226169,0.1215983,0.01368574,0.001372335,0.002641845,0.0008666192,0.0008991871,0.005350325,0.09183114,0.0004820179,0.004693264,0.1339625],"study_design_scores_gemma":[0.4019081,0.5702107,0.0157676,0.00005116504,0.0006194452,0.0005256878,0.0001163136,0.001489976,0.005719351,0.00020472,0.003349673,0.00003731445],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904892,0.002600418,0.0005530255,0.0004472276,0.0001117032,0.003142312,0.0009701245,0.00009791194,0.001587984],"genre_scores_gemma":[0.9920238,0.001345625,0.001107311,0.0005610108,0.0001394082,0.002038717,0.001194544,0.00002479366,0.001564684],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003117995,"threshold_uncertainty_score":0.009200215,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0190295727769518,"score_gpt":0.281547447479599,"score_spread":0.2625178747026472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}